Diabetes News

In an analysis of more than 3 million U.S. adults, most patients with a class 1a recommendation for SGLT2 inhibitors were not prescribed them, researchers reported in the Journal of the American College of Cardiology.

Adults with type 2 diabetes using a GLP-1 receptor agonist are less likely to develop hyperkalemia than those using a DPP-IV inhibitor, according to a study published in JAMA Internal Medicine.

The FDA granted breakthrough device designation to an endoscopic procedure that resurfaces the duodenum lining to help people maintain weight loss after discontinuing GLP-1 receptor agonist treatment, according to a press release.

Worse physical function may be the factor contributing to an increased fracture risk for women aged 75 to 80 years with type 2 diabetes, according to a study published in JAMA Network Open.

Older adults with diabetes who spend less time within their individualized HbA1c target range have a higher risk for developing Alzheimer’s disease and dementias, according to findings published in JAMA Network Open.

Bayer announced positive top-line results for the FINEARTS-HF trial of finerenone, in which the drug reduced risk for cardiovascular death and heart failure events in patients with HF with preserved or mildly reduced ejection fraction.

Quality testing of three counterfeit semaglutide products found low purity and more measured semaglutide than what was on the label, according to a research letter published in JAMA Network Open.

Individuals with type 2 diabetes who received semaglutide had lower probability for medical care related to tobacco dependence compared with other antidiabetes medications, the results of a study in the Annals of Internal Medicine showed.

The FDA has received reports of adverse events, including gastrointestinal events, fainting, headache, migraine, dehydration, acute pancreatitis and gallstones, that may be tied to overdosing with compounded semaglutide.

Drugs used to treat diabetes and obesity, such as GLP-1 receptor agonists, are becoming an important treatment pathway in rheumatology, according to a presenter at the 2024 Association of Women in Rheumatology annual conference.